What is the clinical evidence from this study?

Study design: Review. Population: Obesity, unprovoked deep vein thrombosis, and incidental cancer. Intervention: Integrated cardiometabolic and antithrombotic framework.

What does this research mean for the field?

An integrated clinical framework combining structured occult-cancer screening, cautious GLP-1/GIP-based obesity pharmacotherapy, and apixaban-preferred anticoagulation provides the optimal, evidence-aligned approach for managing patients with obesity, unprovoked DVT, and incidental cancer. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To establish an evidence-based clinical framework integrating occult malignancy screening, targeted obesity pharmacotherapy, and cancer-associated thrombosis management following unprovoked deep vein thrombosis.

July 11, 2026CancersOpen Access

Holistic Management of Obesity in Patients with Incidental Cancer After Unprovoked Deep Vein Thrombosis: A Cardiometabolic and Antithrombotic Framework

Q: What are the key findings of this study?

An integrated framework combining structured occult-cancer screening, judicious obesity pharmacotherapy, and apixaban-preferred anticoagulation offers a rational approach for patients with obesity, unprovoked DVT, and incidental cancer.

View Full Paper

Ask AI

Bookmark

Key result

Integrated cancer screening, obesity pharmacotherapy, and apixaban optimizes management in obesity-associated unprovoked DVT.

Why the study?

Obesity amplifies both thrombotic and oncologic risk, but a unifying framework reconciling occult malignancy screening after unprovoked DVT, contemporary obesity pharmacotherapy, and cancer-associated thrombosis management was needed.

Population

Patients with obesity and incidental cancer after unprovoked DVT

Design

Narrative synthesis based on a structured literature search

Authors

CGCalogero GeraciAlliance Bioversity International - CIAT RCRossella CannarellaUniversity of Catania VMValentina MorelloUniversity of Salento

Discussion

Member takes

Implication

May guide multidisciplinary decisions in this niche population; leaves open whether the proposed framework improves outcomes in prospective trials.

Key Points

To establish an evidence-based clinical framework integrating occult malignancy screening, targeted obesity pharmacotherapy, and cancer-associated thrombosis management following unprovoked deep vein thrombosis.
Conducted a structured literature review of PubMed/MEDLINE, Embase, and Scopus databases spanning January 2000 through March 2025.
Synthesized international guideline recommendations (ISTH, ASH, ESC Cardio-Oncology, EASO) alongside landmark randomized trials evaluating GLP-1/GIP receptor agonists, SGLT2 inhibitors, and direct oral anticoagulants.
Occult cancer is diagnosed in 6–15% of patients within twelve months of unprovoked deep vein thrombosis, justifying age- and sex-specific screening supplemented by FDG-PET/CT in high-risk phenotypes.
In observational cohorts, GLP-1/GIP receptor agonist therapy was associated with a 17% relative reduction in overall cancer incidence (HR 0.83; 95% CI 0.76–0.91), while semaglutide reduced major adverse cardiovascular events by 20% in SELECT (HR 0.80; 95% CI 0.72–0.90; p < 0.001).
Cardioprotective SGLT2 inhibitors lowered cardiovascular death or heart failure worsening (HR 0.74; 95% CI 0.65–0.85) in DAPA-HF and renal outcomes (HR 0.61; 95% CI 0.51–0.72) in DAPA-CKD, while apixaban demonstrated favorable efficacy and bleeding safety for cancer-associated thrombosis.

Structured PICO

Population

Patients with obesity presenting with unprovoked deep vein thrombosis (DVT) and an incidentally detected cancer.

Intervention

An integrated cardiometabolic and antithrombotic framework comprising structured occult-cancer screening (including FDG-PET/CT for high-risk phenotypes), obesity pharmacotherapy (GLP-1/GIP receptor agonists, SGLT2 inhibitors), and apixaban-preferred anticoagulation.

A multidisciplinary framework integrating occult-cancer screening, judicious obesity pharmacotherapy, and apixaban offers an evidence-aligned approach for the complex phenotype of obesity, unprovoked DVT, and incidental cancer.

Limitations

Prospective, dedicated trials in this specific phenotype are urgently warranted.
GLP-1/GIP receptor agonists require cautious use in active cancer due to the risk of accelerating sarcopenia and cachexia.
Patients with severe obesity were underrepresented in pivotal extended-phase cancer-associated thrombosis trials.

Cite This Study

Geraci et al. (2026) conducted a review in Obesity, unprovoked deep vein thrombosis, and incidental cancer. Integrated cardiometabolic and antithrombotic framework was evaluated. An integrated framework combining structured occult-cancer screening, judicious obesity pharmacotherapy, and apixaban-preferred anticoagulation offers a rational approach for patients with obesity, unprovoked DVT, and incidental cancer.

synapsesocial.com/papers/6a51dd5ac18d7f28ca4ffff0 https://doi.org/10.3390/cancers18142212

View Full Paper

Ask AI

Bookmark

Implication

May guide multidisciplinary decisions in this niche population; leaves open whether the proposed framework improves outcomes in prospective trials.

Holistic Management of Obesity in Patients with Incidental Cancer After Unprovoked Deep Vein Thrombosis: A Cardiometabolic and Antithrombotic Framework

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Holistic Management of Obesity in Patients with Incidental Cancer After Unprovoked Deep Vein Thrombosis: A Cardiometabolic and Antithrombotic Framework

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider